HPV Self-Sampling: A Game-Changer in Cervical Cancer Screening

Cervical cancer remains a major public health problem, particularly in populations with limited access to conventional screening services. HPV self-sampling has emerged as a convenient and acceptable approach that can improve participation by allowing women to collect vaginal samples privately without a pelvic examination. This review discusses the principles, clinical performance, benefits, implementation strategies, available devices, challenges, and future applications of HPV self-sampling in cervical cancer screening. Evidence from meta-analyses and clinical studies indicates that self-collected samples tested with validated PCR-based HPV assays provide high diagnostic accuracy for detecting cervical precancer, with reported sensitivity of 90% for CIN2+ and 84% for CIN3+. Self-sampling can improve accessibility, particularly among underserved and under-screened women, while reducing barriers related to privacy, discomfort, and healthcare access. Successful implementation requires validated assays, reliable laboratory systems, appropriate follow-up of HPV-positive women, and integration with existing screening services. HPV self-sampling therefore offers an important opportunity to expand screening coverage and accelerate cervical cancer prevention.